Method of treatment of lichen planus

 

(57) Abstract:

The invention relates to medicine, namely to dermatology, and can be used for the treatment of patients with lichen planus. This injected acyclovir 0.2 g five times a day for 7-10 days and additionally from the 1st day of treatment administered neovir 2 ml intramuscularly every other day, at the rate of 5-10 injections. The method provides a reduction of the clinical manifestations of the disease.

The invention relates to medicine, namely to dermatology, and can be used for the treatment of patients with lichen planus (LP).

KPL - more washausen multifactorial disease with unknown etiology and pathogenesis, it is difficult inferior treatment. The most significant in recent years are viral and immunoallergic concept of development of the disease, which causes an increased interest in the use of antiviral and anti-inflammatory drugs. Often used griseofulvin with anti-inflammatory, antiviral and antitumor effect, and aminoquinolinic derivatives (delagil, plaquenil). Long mnogocentrowoe treatment, often accompanied by toxic effects of the FIPA patients KPL.

As a prototype we have chosen the use of the antiviral drug of methisazone in a daily dose of 20 mg per 1 kg of body weight for 6 days (Sergeev S. J., Pesterev b.p., Labzowsky N. P. et al. //Vestnik St.Petersburg University. dermatol. 1986. 3. c. 63-64). However, therapeutic efficacy of this method is insufficient. Pronounced clinical effect (disappearance of symptoms and significant improvement), the authors noted 27.5% (8 of 29 observed patients).

The objective of the invention is to increase the efficiency of treatment of patients KPL.

The problem is solved in that prescribe antiviral drugs acyclovir 0.2 g five times a day for 7-10 days and additionally from the 1st day of neovir, with an immunostimulating action, 2 ml intramuscularly every other day, at the rate of 5-10 injections (RLS-ENCYCLOPEDIA of DRUGS. The seventh edition, revised and expanded /CH. editor Y. F. Krylov. -M.: radar-2000, 2000. c. 116-117 and S. 629.)

The method was carried out as follows.

After clinical and laboratory examination of the patient KPL prescribed aciclovir aciclovir and neovia. Acyclovir was administered 0.2 g five times (every 4 hours during the day) for 7-10 days; neovir 2 ml (250 mg) vnutorne examination.

The tolerability of the drugs was good, the side effects are not registered.

Treatment of 9 patients underwent LP, including 2 men and 7 women, mean age of 48.7 years (range 26 to 70), the average duration of disease of 5.15 years (range 1 month to 33 years). Only two patients KPL had no comorbidities, most were recorded pathology of the gastrointestinal tract, liver, cardiovascular, nervous system, diabetes mellitus. Prior therapy included antihistamines, efferent, aminoquinolinic, vitamin preparations and external funds.

All patients have cutaneous manifestations were common, half of them (4 people) in the skin was affected mucous membrane of the mouth, and in 2 of them and genitals.

As a result of treatment 1 person reached the disappearance of clinical manifestations, and 4 had significant improvement in 4 - improvement.

Example 1. Patient R., 70, East. bol. 1256. Diagnosis: CMP, bullous form (diagnosis confirmed histologically). The disease duration of 1 month. Concomitant disease: hypertension 2 tbsp. B.

Clinical manifestations abundant, are placed on the skin of the trunk, upper and lower is mirowski on the surface of some of these bubbles. Places papules coalesce into plaques with severe setdataset Wickham. Itching strong. The detected acceleration of ESR (26), the increase in the content of IgG (13,89 g/l) globulin (18,2%).

The patient received within 10 days acyclovir 0.2 g to 5 times a day, neovir intramuscular injection of 2.0 ml through day 5. Was discharged with improvement of the clinical picture. UD decreased. Outpatient not treated. After 3 months, was at the controls, installed complete disappearance papular rash, intense hyperpigmentation at the site of the former elements.

Example 2. Patient X., 62, East. bol. 2474. Diagnosis: KPL. The disease duration of 5 months. Comorbidities: latent diabetes mellitus, hypertension 1 degree alimentary-constitutional Genesis, rubrovaria stop with onychomycosis. Outpatients were treated without effect.

Manifestations PLCs are widespread, localized in the skin mainly the flexor surfaces of the upper and lower extremities, trunk, especially on the rump, where individual papular elements coalesce into large plaques. Papules flat, bluish-red in color with a waxy luster, often with hemorrhagic crusts on the surface. The nails of the hands of the shining, "is about 2 ml intramuscularly 10, given the positive dynamics. Normalization of the content of b-lymphocytes (from 10 to 20%), IgG (from 13.1 to 11.87 per g/l) and IgM (from 1.32 to 1.12 g/l), immunoregulatory index Tx:Twith(IRI) (1.26 to 2,14). The patient was discharged after 10 days with significant improvement: rash on the trunk regressed completely, on the limbs acquired a brownish tint, itching weak.

Example 3. Patient S., 49, East. bol. 2101. Diathesis: KPL. The disease duration of 3 years. Concomitant disease: asthma infectious-allergic and atopic Genesis on the background of diffuse catarrhal bronchitis.

Clinical manifestations are extremely common, grasp the skin of the trunk, in the folds under the Breasts forming garlands, upper limbs, hips, and also the mucous membrane of the mouth and genitals. Papules on the skin are typical of stagnant red, waxy luster, the diameter of 2-5 mm, sometimes coalesce into plaques. In the mouth of small whitish papules located on the mucosa of the cheeks, mainly at the level of closing the teeth, in the form of "fern leaves". The mucosa of small and large labia papules larger, hypertrophic, fused, mainly in powerful conglomeration 2 ml intramuscularly 9 with a positive result, normalization of the erythrocyte sedimentation rate (from 20 to 13 mm/h), the content of b-lymphocytes (from 32 to 22%), Iran (from 1.3 to 2.5).

The patient was discharged with significant improvement: skin rash and mucous membrane of the oral cavity regressed completely, on the genitals significantly uploders. It is recommended to continue treatment for external funds.

Thus, the proposed method has a positive effect on the clinical manifestations and immune status of patients KPL. Treatment was well tolerated and demonstrated for use in the treatment of LP. Pronounced clinical effect (disappearance of symptoms and significant improvement) obtained in 55.5% of cases, which is 2 times higher when compared to the prototype (27,5%).

Method for the treatment of patients with lichen planus, including the appointment of antiviral agents, characterized in that as antiviral drugs prescribed acyclovir 0.2 g five times a day for 7-10 days and additionally from the 1st day of neovir, with an immunostimulating action, 2 ml intramuscularly every other day, on treatment for 5-10 injections.

 

Same patents:
The invention relates to medicine and can be used in the treatment of patients with injuries of tissues of different etiology

The invention relates to medicine, can be used in the production of pharmaceuticals for the treatment of skin lesions

The invention relates to symmetrical triazine derivative, to obtain these compounds and to their use for the protection of organic materials from the harmful effects of ultraviolet radiation
The invention relates to medicine, namely to surgery and traumatology, and for the treatment of frostbite
The invention relates to medicine, namely to dermatology, and can be used in the treatment of psoriasis

The invention relates to medicine and can be used to obtain soft dosage forms intended for the treatment of various fungal infections of the skin
The invention relates to medicine, namely to surgery, and can be used for the treatment of chronic wound healing processes

The invention relates to pharmaceutical and veterinary and provides anti-inflammatory, wound healing and antimicrobial activity
The invention relates to medicine, namely to the bandages used in surgery, dermatology, obstetrics-gynecology and especially when providing first aid in case of injuries and burns and to treat ulcers and bedsores

The invention relates to the field of medicine and relates to a pharmaceutical preparation for prevention and treatment of influenza

The invention relates to chemical-pharmaceutical industry, namely the creation of an effective analgesic, antispasmodic, anti-inflammatory drugs
The invention relates to the field of medicine

The invention relates to medicine and relates to pharmaceutical compositions containing non-steroidal anti-inflammatory compound, at least one connection, reinforcing its pharmacological action, selected from dibasic carboxylic acids, ammonium succinate, amino acids, salts, vitamins, polyphenolic compounds and products containing animal and vegetable origin, as well as the target additive, representing a carbohydrate or sorbent
The invention relates to the field of medicine and relates to a pharmaceutical composition with anti-inflammatory action, including compressed granules of an average size of not more than 3.0 mm, which contain a mixture of naproxen with filler on the carrier matrix, made of polyvinylpyrrolidone, and, optionally, a dye and covered with a layer outrivals

The invention relates to medicine, namely, venereology, and is intended for outpatient treatment of patients with subclinical genital herpes infection (GVI)

The invention relates to medicine, specifically to the means of the treatment of seizures predominantly toxic etiology on the basis of anticonvulsant class of benzodiazepines sibazona

The invention relates to the field of medicine may be used for the treatment of late diabetic complications, namely diabetic polyneuropathy

The invention relates to medicine and relates to the use of esters of 5-aminolevulinic acid for photochemotherapy and diagnosis of cancer, psoriasis, senile keratosis, skin abrasions or scratches, or bacterial, viral or fungal infections

FIELD: medicine, narcology.

SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.

EFFECT: higher efficiency of prophylaxis.

14 cl, 5 ex

Up!